Background: Measuring cell-free (cf)DNA in blood and tissues holds significant potential as a minimally invasive method for disease monitoring in cancer. Cancers arising in the oropharynx and causally linked to human papillomavirus (HPV) represent an ideal model in which to interrogate these methods.
Introduction
Head and neck cancers arising in the oropharynx are often causally related to human papillomavirus (HPV) infection, particularly subtype 16 [1] . Despite favorable outcomes, a significant proportion of HPVþ oropharyngeal cancer (OPC) patients experience incurable locoregionally persistent or recurrent, metastatic disease [2, 3] . Our current tools for monitoring disease progression and treatment response are largely based on examination findings and restaging imaging. Detection of minimal residual disease (MRD), in this case by monitoring a viral marker as a surrogate for disease status, is of significant clinical interest.
There has been significant research interest in developing a liquid biopsy-approach-or monitoring liberated cell-free (cf)DNA circulating in blood and tissues-to genotype tumors non-invasively [4] , monitor treatment response and predict relapse [4, 5] , and provide early detection of cancer [6, 7] . In fact, plasma genotyping of cfDNA has proved clinically useful in detecting epidermal growth factor receptor (EGFR) and KRAS mutations in lung cancer [8] . Given that HPVþ OPCs are often related to high-risk HPV subtypes with viral DNA integrated into the host cell genome and viral-specific oncoproteins [such as early (E) proteins 6 and 7] widely expressed throughout host cells [9, 10] , this entity is an ideal model with which to study circulating tumor DNA. Early approaches, including our own work using serum antibodies to the E6/7 proteins and classical quantitative polymerase chain reaction (qPCR) techniques, were limited in their sensitivity or ability to detect small quantities of circulating or shed protein, or DNA [11] [12] [13] . More recently, droplet digital (dd)PCR has surfaced as a newer method that facilitates ultrasensitive detection of even single copies of DNA-holding significant promise in monitoring and quantification of low-volume targets [14] .
We developed a quantitative and ultrasensitive ddPCR assay for the five dominant high-risk HPV subtypes associated with OPC. We hypothesized that the quantity of plasma HPV cfDNA detected in circulation would correlate with burden of disease, the number and distribution of metastatic sites, and treatment response. To test these hypotheses and validate the assay, we enrolled an observational pilot cohort of advanced HPVþ OPC patients to undergo HPV cfDNA monitoring and correlated viral levels with clinical parameters and treatment outcomes.
Methods

Study participants
We enrolled 22 patients with recurrent, metastatic HPVþ head and neck cancer between August 2017 and April 2018, but 5 (23%) were excluded from analysis (supplementary Figure S1 , available at Annals of Oncology online). All patients consented to an existing institutional review boardapproved protocol permitting collection of blood samples throughout the study (separate from any therapeutic protocol consent). p16 immunoreactivity (>70%) and in situ hybridization or PCR testing was required from tumor samples before enrollment, either from the primary tumor or a metastatic site. Patient enrollment was open to those who were undergoing active surveillance for MRD, or any form of systemic therapy.
Droplet digital PCR for HPV variants
We first developed five ddPCR assays for HPV subtypes 16, 18, 31, 33, and 45. Plasma was spun down from whole blood samples [1500 g for 10 minutes (min)] and cell-free DNA (cfDNA) was extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen). E7 genes from the five dominant high-risk HPV subtypes (16, 18, 31, 33, and 45) , which are causally related to >99% of HPVþ cancers [15] , were cloned into pUC57 plasmids (GenScript) as positive controls. Custom TaqMan Copy Number Variation assays (Applied Biosystems) were designed to recognize each of the five different HPV E7 sequences (supplementary Table  S1 , available at Annals of Oncology online). After emulsification using an Automated Droplet Generator (Bio-Rad), ddPCR cycling conditions were 10 min at 95 C, followed by 40 cycles of a 2-step thermal profile of 15 s at 94 C denaturation and 60 s at 59 C annealing, followed by 10 C hold. Lastly, the 96-well plate was loaded on to and read by a QX100/ QX200 Droplet Reader (Bio-Rad). Results were analyzed using QuantaSoft software (Bio-Rad).
HPV cfDNA monitoring schema
Participants were enrolled on a rolling basis and their first blood sample collection was deemed time 0. Patients were then followed over time and up to five additional plasma collections (average 5.2 per patient) were arranged at 14-21 day intervals during the study period, up to a maximum of 246 elapsed days. Patients therefore entered the study already on active surveillance or on an existing treatment, and based on their disease course then changed treatments when deemed clinically necessary. When possible, plasma draws were coordinated with treatment or protocol visits for convenience and timed around restaging scans and/or changes in therapy. Plasma HPV cfDNA values (copies/ml plasma) were then recorded and analyzed.
Statistical analyses
Tumor burden was calculated as previously described using the largest lesions (!2 mm in any axis, up to three per organ, and up to five total per patient) for each participant [16] . Lymph nodes with a short axis !8 mm were considered evaluable. Total tumor burden (TTB) was then calculated as the sum of the largest diameter of all detectable lesions on imaging (threshold of !2 mm) and determined at the time of enrollment or at the patients first restaging visit. Correlation coefficients were determined using Kendall's tau (s) to test strength of association. A Kruskal-Wallis test was used to compare HPV cfDNA viral levels by subsite of disease. A Mann-Whitney U test was used to evaluate differences in rate of viral load decline among subgroups. Overall survival (OS) was determined from the date of OPC diagnosis (unless otherwise stated) to death from any cause, otherwise this was censored at date of last known follow-upKaplan-Meier statistics were applied using log-rank testing. All P-values reported are two-sided and a P-value <0.05 (*) was considered statistically significant. Data were analyzed using Stata 14.2 (StataCorp LP, College Station, TX).
Results
Clinical characteristics of the cohort
Twenty-two patients treated at our institution with advanced HPVþ OPC were enrolled. The cohort was comprised of almost all males (95%) with the majority being never or minimal (<10 pack-year) former smokers (13, 59%) (supplementary Table S2 , available at Annals of Oncology online). All had evidence of primary oropharyngeal (base of tongue or tonsil) cancer and all had strong and diffuse p16 immunoreactivity. Twelve (55%) had evidence of locoregionally recurrent disease in the head and neck, while 18 (82%) had distant disease (not necessarily mutually exclusive). All patients had previously received some form of cytotoxic therapy or immunotherapy before enrollment.
HPV cfDNA assay development
Before testing cfDNA, we designed (supplementary Appendix S1, available at Annals of Oncology online) and optimized our ddPCR assay. We determined the optimal annealing temperature (59 C) and minimum acceptable TaqMan FAM probe concentration (0.5Â) by running temperature and concentration titrations on HPVE7-cloned plasmids for each variant (supplementary Figure  S2 , available at Annals of Oncology online) These plasmids, as well as NTC wells, were run with each plasma ddPCR batch to aid in demarcating positive (FAM-fluorescent) and negative (nonfluorescent) clusters. Each set of primers/probes were tested individually against each plasmid to verify the specificity between each assay (supplementary Figure S3 , available at Annals of Oncology online). Primers/probes were subsequently multiplexed into a single mastermix to reduce necessary DNA input. Our HPV CNV assays demonstrated linear quantification spanning four orders suggesting that technically ddPCR provides a reliable and quantitative approach to measure HPV variants in plasma.
We were able to discern plasma HPV subtype by ddPCR which matched tumor HPV subtype in all cases (supplementary Figure  S4 , available at Annals of Oncology online). Furthermore, we sought to evaluate the utility of the assay as a diagnostic test using a plasma cfDNA cutoff value of 5-10 copies/ml (supplementary Table S3 , available at Annals of Oncology online).
Correlating tumor burden and location with plasma HPV cfDNA values
The median TTB for the entire cohort was 4.1 (range 0-15.2) (Figure 1 ). TTB strongly correlated with HPV cfDNA viral load (R ¼ 0.91, P ¼ 2.3 Â 10
À6
) at this cohort size (range 0-22855.8 copies/ml). In patients with only locoregionally persistent disease, HPV viral levels did not exceed 12 copies/ml. Similarly, in patients with detectable extra-pulmonary sites of disease, HPV viral levels did not fall below 26.4 copies/ml. Moreover, median HPV viral load increased significantly when stratifying patients by their dominant pattern of disease spread [locoregional disease, 4.6 copies/ml (range 0-66) versus pulmonary-only metastases, 163 copies/ml (range 19.8-22855.8) versus extra-pulmonary distant disease, 452.8 copies/mL (range 26.4-3929.5; P ¼ 0.02)]. More distant anatomic locations generally predicted increasing median HPV cfDNA viral levels, with the exception of bony disease.
Evaluating HPV cfDNA levels as a predictor of treatment response or failure
We followed participants for a median of 133 days (range 14-246) (supplementary Table S4 , available at Annals of Oncology online). Figure 2 graphically depicts the trend in plasma HPV cfDNA over time. We demonstrate that a decrease in plasma HPV cfDNA predicts a decline in tumor burden and captures treatment response. It was especially interesting that patients who demonstrated a clinical response according to restaging scans always experienced a preceding drop in HPV cfDNA. This occurred at a median of 15 days (range 12-20) before restaging scans. We also made note of the difference in slope or degree of viral load decline among patients who seemed to correspond with their therapeutic agent: those who received immunotherapy had a steady decline in plasma HPV cfDNA [median 3.6% per day (range 2.1-4.2), N ¼ 3], whereas those who responded to systemic cytotoxic therapy had increased rates of viral decline [median 5.3% per day (range 3.7-6.1), N ¼ 3] (P ¼ 0.04).
We observed a similar trend among patients who experienced disease progression on therapy (N ¼ 4). Those patients with more significant disease burden (N ¼ 2) had a more rapid increase in their plasma viral load (3.3-fold in <10 days) and this corresponded to the degree of progression observed on restaging imaging. Similar to those patients with clinical benefit, an increase in monitoring viral load was detected in all cases before confirmatory imaging documenting progression of disease. The median time from detection of increasing plasma HPV cfDNA to confirmatory imaging showing progression was 19 days (range 13-38). Beyond earlier detection of response, we show that cfDNA levels accurately recapitulate the natural history of disease among individual patients (supplementary Figure S5 , available at Annals of Oncology online).
Correlating HPV cfDNA values with survival outcomes
OS for the entire cohort is depicted in Figure 3 . Two-year OS was 95.3% and 5-year OS was 66.7% with median OS not yet reached-at a median follow-up time of 26.5 months (range 2-94). When evaluating OS by subsite of disease, patients with locoregional disease or pulmonary-only metastases had worse outcomes compared with to those with extra-pulmonary distant disease (P ¼ 0.01). TTB and median plasma HPV cfDNA viral load correlated with survival (R¼À0.65, P ¼ 0.01; R¼À0.48, P ¼ 0.05, respectively), regardless of therapeutic intervention. Patients with a lower overall tumor burden demonstrated lower median plasma cfDNA values which corresponded with Linear regression modeling applied. *P < 0.05, Kendall's tau for correlation coefficient, two-sided. (E) Median cfDNA levels among the cohort correlated with Royal Marsden Hospital (RMH) prognostic score comprised of LDH, albumin and sites of metastatic disease. A higher score (2-3) is associated with a poor prognosis [17] . *P < 0.05, Mann-Whitney U test, two-sided.
improved survival. Additionally, we used a validated prognostic scoring system [17] accounting for metastatic sites of disease and laboratory parameters to show that cfDNA levels predict outcomes (P < 0.01).
Discussion
Plasma cfDNA monitoring holds enormous clinical potential: from early detection of cancer, to MRD assessment and prognostication. This technology has already proved clinically useful in monitoring the development of acquired resistance in advanced EGFR-mutated non-small-cell lung cancer [8] . Viral monitoring in HPVþ OPC is another setting in which to explore the utility of this platform. Early attempts to use ddPCR in detecting high-risk cervical HPV subtypes commented on its high sensitivity (1.6 copies per sample for HPV16) and suggested that ddPCR may be more accurate than qPCR because of potential bias introduced by qPCR calibration [18] .
We demonstrate that estimated TTB strongly correlated with HPV cfDNA levels at this cohort size (P ¼ 2.3 Â 10 À6 ). Jeannot et al. [12] evaluated a cohort of 70 patients (8 with head and neck cancer) with HPVþ tumors and similarly found that circulating HPV DNA levels (copies/ml) correlated with tumor mass (P < 0.01). Tumors measuring !4.5 cm had higher levels of HPV DNA, and they too demonstrated positive correlation between DNA levels and tumor size (R ¼ 0.51, P < 0.01). They further showed a correlation trend between increasing viral load in circulation and values measured in matched tumor tissue. Our findings corroborate these data and suggest that HPV cfDNA, or shed integrated viral DNA, reflect the overall burden of disease in these patients. Additionally, we show that higher cfDNA levels correlate with more distant sites of disease. Patients with extrapulmonary spread of disease had the highest cfDNA values, with the exception of those with bony involvement. Although speculative, this may be a result of less viral shedding from metastatic osseous foci or difficulty in measuring viral copies emanating from bone metastases.
Regardless of disease response or progression, cfDNA levels began to decline or increase respectively before confirmatory restaging scans in all patients. In fact, patients demonstrated a corresponding change in their HPV cfDNA level a median of 16 days (range 12-38) before restaging scans. A similar trend was observed by Campitelli et al. where sequential serum HPV DNA values were measured in 16 HPVþ cervical carcinoma patients [19] . Similar to our head and neck cohort, circulating DNA values correlated with burden of disease before treatment and predicted disease relapse when monitored over time. Furthermore, we show that the median slope of (%) decline in viral load was significantly greater in those participants responding to cytotoxic systemic therapy, when compared with immunotherapy (P ¼ 0.04). Keeping in mind that cfDNA has a very short half-life (15-20 min), we postulate that cytotoxic chemotherapy results in more direct, rapid cell death and viral cfDNA clearance from the body than immunotherapies, which must recruit and activate immune cells to initiate tumor cell killing. Immunotherapy represents additional challenges in monitoring disease as standard response criteria do not always capture immune-related responses or pseudoprogression. However, a recent case study in a patient with HPVþ anal squamous cell carcinoma treated with the anti-PD-1 agent nivolumab showed a measurable decrease in HPV cfDNA levels with a subsequent plateau in viral load correlating with the individual's partial response to therapy [20] . Our data suggest that HPV cfDNA monitoring captures some of the complexities of tumor kinetics that may be muted by surveillance imaging and difficult to interpret with newer immunotherapies.
It was interesting that patients with locoregional disease in the head and neck or pulmonary-only metastases had worse outcomes compared with those patients with extra-pulmonary distant disease (P ¼ 0.01) at this cohort size. One could argue that head and neck and/or pulmonary involvement affords greater risk for local respiratory organ compromise. Of notable interest was the finding that both TTB and overall median plasma HPV cfDNA viral load negatively correlated with survival, regardless of therapeutic intervention. This finding is fitting given our previous observation that viral load often correlates well with TTB and sites of metastatic disease. Others have shown that higher pretreatment serum HPV DNA levels correlate with nodal burden and staging in untreated HPVþ OPC, using earlier PCR methods [21] . This kind of association has been established in EBVassociated nasopharyngeal carcinoma, where pre-treatment plasma EBV DNA concentration is a powerful predictor of early disease recurrence and prognosis [22] .
Our study has some obvious limitations: we enrolled an observational cohort resulting in a small sample size because metastatic HPVþ OPC is a relatively low-frequency condition. Our findings warrant exploration in newly diagnosed HPVþ OPC patients undergoing definitive therapy. Our multiplexed ddPCR design permits identification of multiple HPV subtypes in a single assay, necessitating reflex tumor testing to confirm the causal variant associated with tumorigenesis if more than one variant is suspected.
In conclusion, we add to an existing small body of literature suggesting that novel ddPCR technologies have the potential to revolutionize clinical management in a variety of cancer types with established protein or viral biomarkers. We developed and validated an ultrasensitive and quantitative ddPCR assay to detect high-risk HPV subtypes among advanced HPVþ OPC patients. We show that viral levels correlate with tumor burden, site of disease, and prognosis. We show that viral kinetics can capture dynamic changes in disease burden to elucidate early treatment response, even with newer immune checkpoint therapies. These early data warrant large-scale, prospective validation in the setting of clinical trials-research that could prove impactful in a wide range of HPV-associated cancers and which is planned at our own institution.
